Vanda Pharmaceuticals (VNDA) EBT (2010 - 2026)

Vanda Pharmaceuticals has reported EBT for 17 years, with the latest figure at -$48.4 million in Q1 2026.

• Quarterly EBT fell 29.59% year-over-year to -$48.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$149.7 million (down 169.13% YoY) and the FY2025 annual result came in at -$138.6 million, down 504.89% from the prior year.
• EBT eased to -$48.4 million in Q1 2026 per VNDA's latest filing, from -$38.0 million in the prior quarter.
• Over five years, EBT peaked at $9.6 million in Q4 2022 and troughed at -$48.4 million in Q1 2026.
• A 5-year average of -$11.3 million and a median of -$5.5 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2024: EBT surged 173.08% in 2023, then tumbled 5103.33% in 2024.
• Over 5 years, EBT stood at $9.6 million in 2022, then plunged by 117.28% to -$1.7 million in 2023, then tumbled by 291.15% to -$6.5 million in 2024, then tumbled by 484.92% to -$38.0 million in 2025, then fell by 27.42% to -$48.4 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$48.4 million, -$38.0 million, and -$28.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.